The cell cvcle is regulated by a number of cyclin-dependent kinases (CdKs). A number of different proteins inhibit the progression through the cell cycle by interference w ith the CdKs. a phenomenon especially interesting in malignant cells. Amonc these proteins are: p27. induced mainlv by cell-cell contact: p2l (WAF-1. CIPI. CDI 1). activ-ated by the tumour-suppressor gene p53 (Pines. 1994 : Mousses et al. 1995 : and p 16 (CDKN2. MfTS I which inhibits CdK4. p16. located on chromosome 9p2 1. is considered to play an important role as a tumour-suppressor gene (Serrano et al. 1993 : Kamb et al. 1994 ). In cell lines of different tumour types. such as lung cancer.
bladder tumours and lymphatic leukaemia. genetic changes in chromosome 9p2 1 have been described in 30-85%7 of cases (Nobori et al. 1994 : Xu et al. 1994 . In fresh solid tumours. the incidence of genetic alterations. such as the homozvgous deletion of p]6. is only in 10-20%. Some studies have been performned to elucidate the role of p16 in breast cancer. applyincg polymerase chain reaction-single strand polymorphism (PCR-SSCP) . Southem blot analysis and other techniques on cell lines and breast carcinoma samples (Kamb et al. 1994 : Bems et al. 1995 : Quesnel et al. 1995 . It was concluded that gene alterations of CDKN2 and the occurrence of genetic damage to the CDKN2 gene in breast cancer are rare events and are not likelyr to be mxvolxed in the carcinogenesis and progression of breast cancer.
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Revised 18 March 1998 Accepted 24 March 1998 Correspondence to: H-P Sinn. PatKoogisches Institut. Universitat Heidelberg. Im Neuenheimer Feld 220. 69120 Heidelberg. Germany Hovwever. a recently published report demonstrated that inactixvation of pi6 occurs in 33%7c of breast cancer cell lines because of aberrant or de novo 5'CpG island methylation of p16 (Herman et al. 1995) .
Few-data pertain to the immunohistochemical detection of p16 alterations in malignant cells. A loss of expression of p16 during the inx asixe stage of tumour progression w-as obserxed in melanocvtic lesions (Reed et al. 1995) .
Immunohistochemistrv is an established method used to analx-se expression and accumulation of many different proteins, including (Rosen and Oberman, 1992) and staged acoding to the TNM system (UICC, 1992) (for details see (Remmele and Stegner, 1987) , receptor positivity was assumed when the semiquantitative score was at least three points (out of a maximum of 12 points).
Flow cytomefty
Tumour samples routinely underwent a cell cycle analysis using DNA flow cytometry as described elsewhere (Feichter et al, 1988 (Feichter et al, . 1989 . Briefly, tumour samples were thoroughly minced with scissors. The nuclei were extracted at room temperature by incubation in acid pepsin (3000 u mg-', Serva, Heidelberg, Germany) dissolved in 100 ml of 0.9 M sodium chloride containing 0.25% hydrochloric acid and carefully stirring for 20 min. After 30 s of sedimentation, 0.5 ml of the supernatant cell suspension was suspended in 1 tg ml-' 4',6-diamindino-2-phenylindole (DAPI) dissolved in Tris-buffer pH 7.8. Minimum incubation time was 30 min. Flow cytometry was carried out using a PAS II flow cytometer equipped with a high-pressure mercury lamp (Partec, Munster, Germany) using the following filters: KG 1, BG 38 and UG 1 for excitation; TK 420 as dichroic mirror, and GG 435 as barrier filter. A flow rate of about 100 counts s-' was maintained by vacuum adjustment. DNA histograms of at least 10 000 counts were ploted. The DNA index of aneuploid cells was expressed as the relative modal DNA value of the aberrant peak in relation to the diploid one. Normal human lymphocytes with a coefficient of variation (CV) of 1.0 were used for calibration of the diploid peak. The cell cycle-phase distribution patterns of the diploid and aneuploid umours were calculated using the Multi-cycle software package (Phoenix Flow Systems, San Diego, CA, USA) after adjustments were made for debris and aggregation (nuclear doublets and triplets). (G2M) Frequently, a simultaneous overexpression of the p53 antigen (using 20% p53 positive tumour nuclei as the cut-off value) was present in tumours displaying cytoplasmic p16 expression. Overexpression of both antigens was demonstrated in more than 50% of the primary tumours (20 out of 33 cases), in 7 out of 12 locoregional recurrences, and in one of the two intraductal carcinomas. When compared with the overall frequency of p53 protein overexpression, the association of p16 overexpression and p53 overexpression was statistically highly significant (Table 3) . Examples of invasive and non-invasive breast carcinomas with simultaneous p16 and p53 overexpression and a high proliferative activity are shown in Figure 1 . In addition, tumours overexpressing p16 or p53 antigens shared a number of histopathological features. In most cases, these tumours were invasive ductal carcinomas with a high grade of malignancy (Table 1) . However, for both tumour suppressor antigens, no relationship to tumour type, size (pT category) or nodal status (pN category) was observed. Other differentiation antigens typically expressed in breast cancers, such as bcl-2, oestrogen receptor (ER) and progesterone receptor (PR), were detectable in only a minority of p16 overexpressing carcinomas (20-27% of p16-positive tumours, all P<0.001 compared with the cytoplasmically p16-negative tumours, Table 3 ). No relationship of p53 or cytoplasmic p16 overexpression with c-erbB-2 expression was observed.
Proliferaion parametrs of p16-and p53-positive tumours The proliferative activity of individual tumours was assessed by determining the Ki67 proliferation index and by DNA flow cytometry. Tumours overexpressing the p16 or p53 antigens showed a highly significantly elevated Ki67 index as compared with the control group (both P<0.0001, Wilcoxon rank-sum test). The median Ki67 index was 60% for tumous with >20% p53-positive cell nuclei and 70% for tumours with 250% cytoplasmic p16 expression, in contrast to 15% and 20% for the non-p53 and nonp16 overexpressing tumours (Figures 2 and 3) .
The median S-phase fraction, as determined by flow cytometry, values were 6.7% for tumours with cytoplasmic p16 staining and 4.6% for tumours with >20% p53 staining (Figures 2  and 3 ), as compared with 4.1% and 4.05% in the control group (P = 0.0027 and P = 0.2, Wilcoxon rank-sum test). Cytoplasmic p16 overexpression had no influence on G2M4 frctions, but G,M was significantly elevated in p53-positive carcinomas (P = 0.015).
All tumours with cytoplasmic p16 expression proved to be aneuploid, the majority had DNA indices between 1 and 2 ( (Hedley, 1993; Sinn et al, 1997) . However, a subset of mammary carcinomas displays an accelerated proliferation. Different mechanisms are known to be responsible for the loss of cell cycle control, most importantly the inactivation of tumour-suppressor genes in conjunction with activation of cyclin-dependent kinases and cyclins (Hunter and Pines. 1994; Sherr, 1994) . The classical mechanism of inactivation of tumour-suppressor genes in carcinogenesis is through homozygous inactivation of both alleles and was elucidated in retinoblastoma (Goodrich and Lee, 1993) . Inactivation of tumour-suppressor genes may occur through different mechanisms, as is the case with p53, and may lead to overexpression of the protein (Nigro et al, 1989; Lane, 1992) . p53 overexpression was found to be associated with hyperproiferation of the tumours (Isola et al, 1992; Allred et al, 1993) . The p16 tumour-suppressor gene is known to be vital for the regulation of the cell cycle at the G1 checkpoint (Kamb, 1995; Koh et al, 1995; Enders et al, 1996) , but little is known about possible p16 alterations in breast cancer. In contrast to other tumour-suppressor genes, point mutations of the p16 gene were detected only sporadically in primary breast carcinomas (Xu et al, 1994; Quesnel et al, 1995) . However, a high percentage of homozygous pi6 deletion was observed in breast cancer cell lines (Kamb et al, 1994; Xu et al, 1994; Cairns et al, 1995) . Recently, another mechanism of p16 inactivation, hypermethylation of the pi6 promoter region, was described in breast carcinoma (Herman et al, 1995; Merlo et al, 1995) .
On the protein level, evidence has shown that the p16 protein may be inactivated in up to 49% of primary breast carcinomas (Geradts and Wilson, 1996) . This immunohistochemical observation has also been made in head and neck carcinomas (Reed et al, 1996) and malignant melanoma (Reed et al, 1995 breast carcinomas with an aberrant cytoplasmic accumulation of this protein, a finding previously described only in breast carcinoma cell lines (Okamoto et al. 1994b /, Geradts et aL 1995 . Human cell lines lacking functional retinoblastoma protein (pRB) were found to contain high levels of pl6 RNA and protein. suggesting a negative feedback loop by which pRB might regulate p16 expression in late G, phase of the cell cycle (Hara et al. 1996) . The product of the CDKN2 gene (pl6) inhibits phosphorylation of the retinoblastoma protein (pRB) and thus acts as a negative cell cycle regulator.
Consequently, an inverse relationship has previously been described for p16 protein levels and RB expression in human cell lines (Hara et al, 1996; Maelandsmo et al, 1996) . Our data suggest a similar relationship between pRB expression and p16 protein accumulation for pnrmary breast cancers because we observed a frequent loss of pRB expression in tumours with accumulation of the p16 protein.
On a functional basis, our results also suggest that this aberrant expression of p16 is associated with concurrent loss of its function and hyperproliferation of the tumour cell. The unusually high proliferation rate of tumours with cytoplasmic p16 expression seems to indicate an underlying defect of the p16 gene or some other gene. because there were no alterations detectable with PCR-SSCP and direct DNA sequencing techniques in the pl6 gene itself in the tumour cell lines tested. As mentioned above. this altered gene may be the RB gene. The accumulation of p16 protein may also be due to some kind of disturbance related to the normal function of the protein. or to a defect of the pi6 gene that is not detectable by the techniques applied in this study. On a morphological basis. tumours with stabilization of the p53 protein are different from tumours with p16 protein stabilization because p53 accumulation occurs typically in the nucleus, while p16 accumulation was seen within the cytoplasm. However, both in tumours with p53 or with p16 accumulation, the S-phase fractions were elevated, had poor grade of differentiation and the loss of hormone receptors was common. These observations and the lack of correlation with lymph node status and tumour size were described for breast carcinomas with p53 accumulation previously (Friedrichs et al. 1993; Beck et al. 1995; Charpin et al. 1995) . Therefore, it appears that aberrant expression of the pl6 or p53 proteins are very early changes in the progression of breast carcinoma. and do not change significantly with tumour progression.
In summary. we have demonstrated that there is a subset of poorly differentiated. rapidly proliferating and ER/PR-negative breast cancers that show aberrant cytoplasmic p16 accumulation as detected by immunohistochemical staining. Therefore, accumulation of the p16 protein could serve as an important biological marker for the identification of highly malignant breast carcinomas.
